ABBVIE B.V.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 29226
 
  
 
C07D HETEROCYCLIC COMPOUNDS 23139
 
  
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 887
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 445
 
  
 
C07K PEPTIDES 2134
 
  
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 1137
 
  
 
C07F ACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM, OR TELLURIUM 169
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 198
 
  
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 1124

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2011/0257,158 PRECOMPACTED FAST-DISINTEGRATING FORMULATIONS OF COMPOUNDS WITH A LOW ORAL BIOAVAILABILITYDec 17, 09Oct 20, 11[A61K, A61P]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9670220 Fused heterocyclic derivatives as S1P modulatorsJun 18, 15Jun 06, 17[A61K, A01N, C07D]
9662337 Bisaryl (thio)morpholine derivatives as S1P modulatorsDec 03, 15May 30, 17[A61K, C07D]
9227960 Bisaryl (thio)morpholine derivatives as S1P modulatorsMar 23, 15Jan 05, 16[C07D]
9096612 Fused heterocyclic derivatives as S1P modulatorsSep 05, 13Aug 04, 15[A01N, C07D]
9029371 Bisaryl (thio)morpholine derivatives as S1P modulatorsJul 08, 11May 12, 15[A61K, C07D]
8937184 1H-imidazole derivatives as cannabinoid CB2 receptor modulatorsFeb 14, 06Jan 20, 15[C07D]
8796262 Fused heterocyclic derivatives as S1P modulatorsJul 08, 11Aug 05, 14[A61K, A01N, C07D]
8735388 Heterocyclic compounds with affinity to muscarinic receptorsOct 16, 13May 27, 14[A61K, A01N, C07D]
8586606 Heterocyclic compounds with affinity to muscarinic receptorsNov 21, 11Nov 19, 13[A61K, A01N, C07D]
8575148 Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockersDec 10, 09Nov 05, 13[A61K, C07D, A61P]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2012/0208,185 METHOD FOR DETERMINING THE RISK OF DEVELOPING A NEUROLOGICAL DISEASEAbandonedNov 21, 11Aug 16, 12[C12Q, G01N]
7608718 -antagonistic activityExpiredNov 03, 05Oct 27, 09[A61K, C07D]
7498348 1 H-imidazole derivatives as cannabinoid receptor modulatorsExpiredAug 21, 07Mar 03, 09[A61K]
7459279 Binding assay employing IGS4, a human G-protein coupled neuromedin receptorExpiredJun 30, 05Dec 02, 08[G01N]
7459292 Polynucleotides and expression system of a novel human G-protein coupled receptorExpiredJun 30, 05Dec 02, 08[C12N]
6998255 Human G-protein coupled receptorExpiredSep 25, 00Feb 14, 06[C07K]
6998398 Solid salts of benzazepine compounds and pharmaceutical compositions containing themExpiredJul 14, 04Feb 14, 06[C07D]
2006/0013,874 Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-- 2-oneAbandonedJul 12, 05Jan 19, 06[A61K]
6974810 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activityExpiredSep 17, 02Dec 13, 05[A61K, C07D]
6958396 8-{4-[3-(5-fluoro-1H-indol-3-YL)-Propyl]-Piperazin-1-YL}-2-methyl-4H-Benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake siteExpiredFeb 19, 02Oct 25, 05[A61K, C07D]
2005/0215,567 1-[2H-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of painAbandonedMar 22, 05Sep 29, 05[A61K]

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.